Katherine A Johansen Taber, Barry D Dickinson Department of Science and Biotechnology, American Medical Association, Chicago, IL, USA Background: The use of pharmacogenomic testing in the clinical setting has the potential to improve the safety and effectiveness of drug therapy, yet studies have revealed that physicians lack knowledge about the topic of pharmacogenomics, and are not prepared to implement it in the clinical setting. This study further explores the pharmacogenomic knowledge deficit and educational resource needs among physicians. Materials and methods: Surveys of primary care physicians, cardiologists, and psychiatrists were conducted. Results: Few physicians reported familiarity with the topic of pharmacogenomics, but more ...
Background: Considerable progress has been made in the way of pharmacogenetic research and the ...
Background: Despite evidence of clinical utility and the availability of prescription guidelines, ph...
Rachel Mills,1 Deepak Voora,1,2 Bruce Peyser,3 Susanne B Haga1,2 1Duke Institute for Genome Sciences...
Background: Genetic differences account for an outsized amount of patient variation in drug response...
The ideal of individualized patient care is not a uniquely new concept. The history of pharmacogenet...
Abstract Background Genetic testing, especially in pharmacogenomics, can have a major impact on pati...
Pharmacogenomics provides a personalized approach to pharmacotherapy by using genetic information to...
Objectives: This study assesses pharmacists\u27 (both community and hospital) perception of usefulne...
Tests that feature genomic indicators can now be used to guide the pharmacological treatment of pati...
Introduction This study was designed to assess the depth, breadth, and perception of pharmacogenomic...
Response to a drug often differs widely among individual patients. This variability is frequently ob...
Background: Presently knowledge of pharmacogenomics is important for therapeutic purposes as well as...
Background: As pharmacogenomics (PGx), a component of genetics/genomics and precision medicine, gain...
Pharmacists are expected to play an important role in applying pharmacogenetic discoveries to patien...
The clinical uptake of pharmacogenomic (PGx) testing and genotype-based prescribing has been disappo...
Background: Considerable progress has been made in the way of pharmacogenetic research and the ...
Background: Despite evidence of clinical utility and the availability of prescription guidelines, ph...
Rachel Mills,1 Deepak Voora,1,2 Bruce Peyser,3 Susanne B Haga1,2 1Duke Institute for Genome Sciences...
Background: Genetic differences account for an outsized amount of patient variation in drug response...
The ideal of individualized patient care is not a uniquely new concept. The history of pharmacogenet...
Abstract Background Genetic testing, especially in pharmacogenomics, can have a major impact on pati...
Pharmacogenomics provides a personalized approach to pharmacotherapy by using genetic information to...
Objectives: This study assesses pharmacists\u27 (both community and hospital) perception of usefulne...
Tests that feature genomic indicators can now be used to guide the pharmacological treatment of pati...
Introduction This study was designed to assess the depth, breadth, and perception of pharmacogenomic...
Response to a drug often differs widely among individual patients. This variability is frequently ob...
Background: Presently knowledge of pharmacogenomics is important for therapeutic purposes as well as...
Background: As pharmacogenomics (PGx), a component of genetics/genomics and precision medicine, gain...
Pharmacists are expected to play an important role in applying pharmacogenetic discoveries to patien...
The clinical uptake of pharmacogenomic (PGx) testing and genotype-based prescribing has been disappo...
Background: Considerable progress has been made in the way of pharmacogenetic research and the ...
Background: Despite evidence of clinical utility and the availability of prescription guidelines, ph...
Rachel Mills,1 Deepak Voora,1,2 Bruce Peyser,3 Susanne B Haga1,2 1Duke Institute for Genome Sciences...